Clinical Trials
16
Active:0
Completed:11
Trial Phases
2 Phases
Phase 1:4
Phase 2:10
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (14 trials with phase data)• Click on a phase to view related trials
Phase 2
10 (71.4%)Phase 1
4 (28.6%)99mTc Sestamibi SPECT/CT vs 18F Fluorocholine PET/CT
Phase 2
Recruiting
- Conditions
- Parathyroid Adenoma
- Interventions
- Drug: 18Fluorocholine
- First Posted Date
- 2023-06-07
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Andrei Iagaru
- Target Recruit Count
- 100
- Registration Number
- NCT05891769
- Locations
- 🇺🇸
Stanford Hospital and Clinics, Stanford, California, United States
Study Evaluating 111In-Panitumumab for Nodal Staging in Head and Neck Cancer
Phase 1
Recruiting
- Conditions
- Head and Neck Cancer
- Interventions
- Procedure: Single photon emission computed tomography/computed tomography (SPECT/CT) scans
- First Posted Date
- 2021-04-12
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Andrei Iagaru
- Target Recruit Count
- 28
- Registration Number
- NCT04840472
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer
Phase 2
Terminated
- Conditions
- Prostate Cancer
- Interventions
- Drug: 68-Ga RM2.Drug: 68-Ga PSMA11Device: PET/MRI
- First Posted Date
- 2020-02-11
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Andrei Iagaru
- Target Recruit Count
- 4
- Registration Number
- NCT04264208
- Locations
- 🇺🇸
Stanford Cancer Center, Stanford, California, United States
68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU Therapy
Phase 1
Completed
- Conditions
- Prostate Cancer
- Interventions
- Drug: 68-Ga RM2Drug: 68-Ga PSMA11Device: Investigational software and coils in PET/MR ScanProcedure: PET/MRI
- First Posted Date
- 2019-05-14
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Andrei Iagaru
- Target Recruit Count
- 14
- Registration Number
- NCT03949517
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer
Phase 1
Completed
- Conditions
- Estrogen Receptor PositiveBreast Carcinoma
- Interventions
- Procedure: Magnetic Resonance ImagingProcedure: Positron Emission TomographyDevice: Investigational software and coils in PET/MR scan
- First Posted Date
- 2019-02-06
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- Andrei Iagaru
- Target Recruit Count
- 5
- Registration Number
- NCT03831711
- Locations
- 🇺🇸
Stanford Cancer Institute Palo Alto, Palo Alto, California, United States
- Prev
- 1
- 2
- 3
- 4
- Next
News
No news found